Sana reports positive six-month data for islet cell therapy in type 1 diabetes without immunosuppression

Sana Biotechnology, Inc.

Six-month results: transplanted allogeneic islet cells (UP421) safe, survive, evade immune system, produce insulin without immunosuppression.
C-peptide detectable fasting and increases with mixed meal tolerance test, confirming insulin secretion; MRI shows graft survival at 6 months.
No safety issues; HIP-modified cells evade both allogeneic and autoimmune responses in type 1 diabetes patient.
Sana plans to file IND for SC451 (stem cell-derived HIP islet therapy) as soon as next year, incorporating UP421 learnings.
Data presented at ADA 85th Scientific Sessions; study funded by Helmsley Charitable Trust, partnership with Uppsala University Hospital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.